Skip to main content
SpringerLink
Log in

Comment on: “Limited Evidence for Risk Factors for Proarrhythmia and Sudden Cardiac Death in Patients Using Antidepressants: Dutch Consensus on ECG Monitoring”

  • Letter to the Editor
  • Published:
Drug Safety Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 17 August 2018

The Original Article was published on 26 February 2018

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Simoons M, Seldenrijk A, Mulder H, Birkenhäger T, Groothedde-Kuyvenhoven M, Kok R, et al. Limited evidence for risk factors for proarrhythmia and sudden cardiac death in patients using antidepressants: Dutch consensus on ECG monitoring. Drug Saf. 2018;41:655–64.

    Article  CAS  Google Scholar 

  2. Wiles NJ, Thomas L, Turner N, Garfield K, Kounali D, Campbell J. Long-term effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: follow-up of the CoBalT randomised controlled trial. Lancet Psychiatry. 2016;3:137–44.

    Article  Google Scholar 

  3. McHugh RK, Whitton SW, Peckham AD, Welge JA, Otto MW. Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review. J Clin Psychiatry. 2013;7:595–602.

    Article  Google Scholar 

  4. Gartlehner G, Gaynes BN, Amick HR, Asher GN, Morgan LC, Coker-Schwimmer E, et al. Comparative benefits and harms of antidepressant, psychological, complementary, and exercise treatments for major depression: an evidence report for a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;164:331–41.

    Article  Google Scholar 

  5. Jureidini JN, Amsterdam JD, McHenry LB. The citalopram CIT-MD-18 pediatric depression trial: deconstruction of medical ghostwriting, data mischaracterisation and academic malfeasance. Int J Risk Saf Med. 2016;28:33–43.

    Article  Google Scholar 

  6. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358:252–60.

    Article  CAS  Google Scholar 

  7. Moncrieff J, Kirsch I. Empirically derived criteria cast doubt on the clinical significance of antidepressant-placebo differences. Contemp Clin Trials. 2015;43:60–2.

    Article  Google Scholar 

  8. Ebrahim S, Bance S, Athale A, Malachowski C, Ioannidis JP. Meta-analyses with industry involvement are massively published and report no caveats for antidepressants. J Clin Epidemiol. 2016;70:155–63.

    Article  Google Scholar 

  9. Prescrire. Towards better patient care: drugs to avoid in 2017. Rev Prescrire. 2017;37(400):137–48. http://english.prescrire.org/en/2E7D1F64A7BCA9110350CFD2BA4AF951/Download.aspx. Accessed 11 June 2018.

  10. Friedman RA. Antidepressants’ black-box warning—10 years later. N Engl J Med. 2014;371:1666–8.

    Article  Google Scholar 

  11. Catalano G, Catalano MC, Epstein MA, Tsambiras PE. QTc interval prolongation associated with citalopram overdose: a case report and literature review. Clin Neuropharmacol. 2001;24:158–62.

    Article  CAS  Google Scholar 

  12. Ojero-Senard A, Benevent J, Bondon-Guitton E, Durrieu G, Chebane L, Araujo M, et al. A comparative study of QT prolongation with serotonin reuptake inhibitors. Psychopharmacology (Berl). 2017;234:3075–81.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Hospital, 80000, Amiens, France

    Alain Braillon

Authors
  1. Alain Braillon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alain Braillon.

Ethics declarations

Funding

No sources of funding were used to assist in the preparation of this letter.

Conflict of interest

Alain Braillon has no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Braillon, A. Comment on: “Limited Evidence for Risk Factors for Proarrhythmia and Sudden Cardiac Death in Patients Using Antidepressants: Dutch Consensus on ECG Monitoring”. Drug Saf 41, 1415–1416 (2018). https://doi.org/10.1007/s40264-018-0714-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-018-0714-7

Search

Navigation